1.
Targeting HER2 in the treatment of non-small cell lung cancer
by Mar, Nataliya
Lung cancer (Amsterdam, Netherlands), 2015, Vol.87 (3), p.220-225
2.
Current trends in the treatment of HR+/HER2+ breast cancer
by Kay, Charlene
Future oncology (London, England), 2021-03-01, Vol.17 (13), p.1665-1681
3.
HER2 gene mutations in non-small cell lung carcinomas: Concurrence with her2 gene amplification and her2 protein expression and phosphorylation
by Suzuki, Mikiko
Lung cancer (Amsterdam, Netherlands), 2014, Vol.87 (1), p.14-22
4.
Impact of the 2013 ASCO/CAP HER2 Guideline Updates at an Academic Medical Center That Performs Primary HER2 FISH Testing: Increase in Equivocal Results and Utility of Reflex Immuno...
by Muller, Kristen E
American journal of clinical pathology, 2015-08, Vol.144 (2), p.247-252
5.
ER staining levels affect HER2 staining and heterogeneity
by Akashi, Momoko
Breast cancer (Tokyo, Japan), 2021-01-09, Vol.28 (3), p.720-726
6.
Analysis of plasma HER2 copy number in cell-free DNA of breast cancer patients: a comparison with HER2 extracellular domain protein level in serum
by Qui, Shi
Breast cancer (Tokyo, Japan), 2021-02-04, Vol.28 (3), p.746-754
7.
A phase III trial of alpelisib + trastuzumab ± fulvestrant versus trastuzumab + chemotherapy in HER2
Future oncology (London, England), 2022-04-01, Vol.18 (19), p.2339-2349
8.
A real-world US study of recurrence risks using combined clinicopathological features in HR-positive, HER2-negative early breast cancer
by Sheffield, Kristin M
Future oncology (London, England), 2022-07-01, Vol.18 (21), p.2667-2682
9.
Cryoablation: A promising non-operative therapy for low-risk breast cancer
by Habrawi, Zaina
The American journal of surgery, 2021-01, Vol.221 (1), p.127-133
10.
Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study
by Banerji, Udai
The lancet oncology, 2019-08, Vol.20 (8), p.1124-1135
11.
Advantages and Disadvantages of Technologies for HER2 Testing in Breast Cancer Specimens
by Furrer, Daniela
American journal of clinical pathology, 2015-11-01, Vol.144 (5), p.686-703
12.
Achieving 95% Cross-Methodological Concordance in HER2 Testing: Causes and Implications of Discordant Cases
by GRIMM, Erin E
American journal of clinical pathology, 2010, Vol.134 (2), p.284-292
13.
Single HER2-positive tumor cells are detected in initially HER2-negative breast carcinomas using the DEPArray™–HER2-FISH workflow
by Grüntkemeier, Lisa
Breast cancer (Tokyo, Japan), 2022-01-13, Vol.29 (3), p.487-497
14.
Trastuzumab emtansine (T-DM1) for HER2-positive breast cancer
by Boyraz, Baris
Current medical research and opinion, 2013-04, Vol.29 (4), p.405-414
15.
Heterologous human/rat HER2-specific exosome-targeted T cell vaccine stimulates potent humoral and CTL responses leading to enhanced circumvention of HER2 tolerance in double trans...
by Xie, Yufeng
Vaccine, 2018-03-07, Vol.36 (11), p.1414-1422
16.
HER2 Gene Protein Assay Is Useful to Determine HER2 Status and Evaluate HER2 Heterogeneity in HER2 Equivocal Breast Cancer
by Hou, Yanjun
American journal of clinical pathology, 2017-01-01, Vol.147 (1), p.89-95
17.
Comparison of HER2 Dual-Color and Fluorescence In Situ Hybridization in Breast Cancer
by Shao, Tiffany
American journal of clinical pathology, 2016-09, Vol.146 (3), p.339-345
18.
MAHOGANY: margetuximab combination in HER2+ unresectable/metastatic gastric/gastroesophageal junction adenocarcinoma
by Catenacci, Daniel Vt
Future oncology (London, England), 2020-12-01, Vol.17 (10), p.1155-1164
19.
Breast cancer vaccines delivered by dendritic cell-targeted lentivectors induce potent antitumor immune responses and protect mice from mammary tumor growth
by Bryson, Paul D
Vaccine, 2017-10-13, Vol.35 (43), p.5842-5849
20.
Irreversible inhibition of Δ16HER2 is necessary to suppress Δ16HER2-positive breast carcinomas resistant to Lapatinib
by Tilio, Martina
Cancer letters, 2016, Vol.381 (1), p.76-84
